ClinicalTrials.gg
CompletedNCT06598995MB in oHCMUpdated Sep 19, 2024

Myocardial Bridging in Obstructive Hypertrophic Cardiomyopathy

An observational study in Myocardial Bridging, Obstructive Hypertrophic Cardiomyopathy and Atrial Fibrillation (AF), sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
968
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 71 studies in Cardiomyopathy, Hypertrophic with a site in China — 30 open to participants now, 43 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · China.

Enrollment
12th of 32
968 · median 608
Started
2022
with 8 others
Observational
32 of 71
14 open now
Registered
47th of 71
by date
Lead sponsor
4 of 71
Chinese Academy of Medical Sciences, Fuwai Hospital

Among the 71 studies in Cardiomyopathy, Hypertrophic with a site in China, this one is the 12th largest by enrollment of the 32 observational ones that give a count, is one of 9 that started in 2022, is one of 32 observational ones, and was the 47th registered.

Cardiomyopathy, Hypertrophic

364 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 117 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

30 of the 71 studies in Cardiomyopathy, Hypertrophic with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Cardiomyopathy, Hypertrophic with a site in China, or all of them as a file.
02

Study summary

This study investigated the impact of myocardial bridging (MB) and its characteristics on preoperative atrial fibrillation and survival in patients with obstructive hypertrophic cardiomyopathy (oHCM). We recruited 968 consecutive patients with oHCM who underwent myectomy at our institution between January 2015 and December 2019, including 144 patients with MB and 824 patients without MB. All patients received angiography before surgery. The diagnosis of preoperative atrial fibrillation was based on 12-lead electrocardiography, 24-hour Holter electrocardiography, or in-hospital electrocardiogram monitoring, which was extracted from patients' medical records. Surgical details and follow-up data were also collected.

03

Conditions studied

  • Myocardial Bridging
  • Obstructive Hypertrophic Cardiomyopathy
  • Atrial Fibrillation (AF)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients diagnosed with obstructive hypertrophic cardiomyopathy who underwent septal myectomy.

Eligibility criteria

Inclusion Criteria:I(i) age ≥ 18 years and (ii) diagnosis of oHCM based on clinical and echocardiographic evaluation.

-

Exclusion Criteria: (i) a history of heart surgery (ii) Patients who had coronary atherosclerosis or myocardial infraction; (iii) Patients who had no angiography records.

-

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
968 participants (actual)
Patient registry
No

Groups and cohorts

  • Obstructive hypertrophic cardiomyopathy who underwent septal myectomy

    All patients underwent angiography and without other coronary artery disease.

    Procedure: Coronary artery bypass grafting or unroofing

Interventions

  • ProcedureCoronary artery bypass grafting or unroofing

    Patients had an MB with \>75% compression degree would receive coronary artery bypass grafting, and those who underwent unroofing may had a depth of MB \< 5mm (whether deal with these MB with a depth \<5mm depends on the surgeon and the period time of patients received a surgery).

06

What researchers measure

Primary outcomes

  1. All-cause death

    Any death occurred one month after discharge

    Time frame: One month after discharge

Secondary outcomes

  1. New-onset AF

    Patients did not have AF before surgery, and AF occurred one month after discharge.

    Time frame: One month after discharge.

  2. Composite endpoints

    Composite endpoints including all-cause death, new-onset AF, and readmission due to heart failure, stroke, and other cardiovascular events (such as myocardial infarction, arrhythmia).

    Time frame: One month after discharge

07

Study locations

1 site
  • Fuwai Hospital
    Beijing, Please Select 475, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Dec 2022, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2024
First posted
Sep 19, 2024
StartActual
Jan 1, 2022
Primary completionActual
Dec 31, 2022
CompletionActual
Dec 31, 2022
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06598995
Responsible party
Changrong Nie (MD, Chinese Academy of Medical Sciences, Fuwai Hospital) — Principal investigator
First posted
Sep 19, 2024
Start date
Jan 1, 2022
Primary completion
Dec 31, 2022
Completion
Dec 31, 2022
Last update
Sep 19, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion